Opthea (OPT AU): Kicks Off A$80M Capital Raise To Support Phase 3 Trial of Lead Drug Candidate
Opthea will raise A$80M via a combination of private placement and accelerated non-renounceable right offer. Proceeds from the offer and existing...
422 Views
Opthea Ltd (OPT AU): Secured Funds as Lead Eye Drug Candidate Advancing in Phase 3 Trials
Opthea secured up to $170M financing from Carlyle and done $90M equity financing placement. The company’s successful fund raising is an affirmation...
263 Views
Imugene (IMU AU): Clinical Trial Continued to Advance; Cash Position Still Strong
Imugene has dosed first patient from the third cohort of the Checkvacc phase 1 clinical trial. The company’s cash position is strong and can...
239 Views
Opthea Ltd (OPT AU): Lead Asset for Highly Prevalent Retinal Disease Moving Toward Commercialization
Opthea’s OPT-302 is in phase 3 trial for wet AMD. While we are upbeat about the multi-billion-dollar market opportunity of OPT-302, the company’s...
208 Views
Opthea Limited - Eyeing the Global Opportunity in Retinal Diseases
Opthea Limited Eyeing the global opportunity in retinal diseases Opthea Ltd (ASX:OPT) is a clinical-stage biotechnology company focused on...
818 Views